Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.
Aged
Aged, 80 and over
Bone Density
/ drug effects
Bone Density Conservation Agents
/ administration & dosage
Comorbidity
Drug Administration Schedule
Humans
Japan
/ epidemiology
Kidney Function Tests
Male
Middle Aged
Osteoporosis
/ epidemiology
Prostatic Neoplasms
/ epidemiology
Public Health Surveillance
Retrospective Studies
Risk Factors
Spinal Fractures
/ epidemiology
Zoledronic Acid
/ administration & dosage
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
17 Apr 2021
17 Apr 2021
Historique:
received:
14
01
2021
accepted:
08
04
2021
entrez:
17
4
2021
pubmed:
18
4
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Androgen deprivation therapy (ADT) is the effective treating prostate cancer but is often accompanied by cancer treatment-induced bone loss (CTIBL), which impairs the patient's quality of life. In patients with nonmetastatic castration-sensitive prostate cancer (M0CSPC) who already have osteoporosis before starting ADT, appropriate bone-modifying agent intervention must be performed in parallel, as the patient has a high risk of future fracture. However, little is known about therapeutic interventions aimed at preventing the progression of CTIBL and new fractures. The present study explored the effect of once-yearly zoledronic acid 5 mg (ZOL 5 mg) on bone mineral density (BMD) and new vertebral fractures (VFs) in M0CSPC patients with coexisting osteoporosis before starting ADT. We conducted a retrospective, multi-institutional, cohort study involving 42 M0CSPC patients with osteoporosis who had undergone ADT with/without a single intravenous infusion of ZOL 5 mg at the start of ADT (ZOL 5 mg group, n = 26; control group, n = 16). The association of the ZOL 5 mg with changes in the BMD from baseline to 12 months and the incidence of VFs were evaluated. Prevalent VFs were found in 47.6% of all patients at baseline. ZOL 5 mg significantly increased the lumbar spine BMD (LS-BMD) (mean rate of change: + 4.02%, p < 0.0001) and significantly decreased the TRACP-5b (mean rate of change: - 52.1%, p < 0.0001) at 12 months after starting ADT. Incident VFs were identified in 19.0% of all patients at 12 months after starting ADT. After adjusting for the age, BMI, and changes in the LS-BMD, ZOL 5 mg was not significantly associated with incident VFs (odds ratio 0.66, 95% confidence interval 0.04-11.3, p = 0.7774). ZOL 5 mg significantly increased the LS-BMD 12 months after starting ADT, and our short-term results showed that ZOL 5 mg was not significantly correlated with the suppression of incident vertebral fractures.
Sections du résumé
BACKGROUND
BACKGROUND
Androgen deprivation therapy (ADT) is the effective treating prostate cancer but is often accompanied by cancer treatment-induced bone loss (CTIBL), which impairs the patient's quality of life. In patients with nonmetastatic castration-sensitive prostate cancer (M0CSPC) who already have osteoporosis before starting ADT, appropriate bone-modifying agent intervention must be performed in parallel, as the patient has a high risk of future fracture. However, little is known about therapeutic interventions aimed at preventing the progression of CTIBL and new fractures. The present study explored the effect of once-yearly zoledronic acid 5 mg (ZOL 5 mg) on bone mineral density (BMD) and new vertebral fractures (VFs) in M0CSPC patients with coexisting osteoporosis before starting ADT.
METHODS
METHODS
We conducted a retrospective, multi-institutional, cohort study involving 42 M0CSPC patients with osteoporosis who had undergone ADT with/without a single intravenous infusion of ZOL 5 mg at the start of ADT (ZOL 5 mg group, n = 26; control group, n = 16). The association of the ZOL 5 mg with changes in the BMD from baseline to 12 months and the incidence of VFs were evaluated.
RESULTS
RESULTS
Prevalent VFs were found in 47.6% of all patients at baseline. ZOL 5 mg significantly increased the lumbar spine BMD (LS-BMD) (mean rate of change: + 4.02%, p < 0.0001) and significantly decreased the TRACP-5b (mean rate of change: - 52.1%, p < 0.0001) at 12 months after starting ADT. Incident VFs were identified in 19.0% of all patients at 12 months after starting ADT. After adjusting for the age, BMI, and changes in the LS-BMD, ZOL 5 mg was not significantly associated with incident VFs (odds ratio 0.66, 95% confidence interval 0.04-11.3, p = 0.7774).
CONCLUSION
CONCLUSIONS
ZOL 5 mg significantly increased the LS-BMD 12 months after starting ADT, and our short-term results showed that ZOL 5 mg was not significantly correlated with the suppression of incident vertebral fractures.
Identifiants
pubmed: 33863312
doi: 10.1186/s12885-021-08177-w
pii: 10.1186/s12885-021-08177-w
pmc: PMC8052675
doi:
Substances chimiques
Bone Density Conservation Agents
0
Zoledronic Acid
6XC1PAD3KF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
422Références
J Urol. 2003 Jun;169(6):2008-12
pubmed: 12771706
J Urol. 2009 Nov;182(5):2257-64
pubmed: 19758618
Prostate Cancer. 2011;2011:176164
pubmed: 22110981
BJU Int. 2014 Sep;114(3):344-53
pubmed: 24512527
Clin Lab. 2006;52(9-10):499-509
pubmed: 17078477
Bone. 2004 Aug;35(2):375-82
pubmed: 15268886
Am J Mens Health. 2018 Nov;12(6):1958-1965
pubmed: 30095034
Osteoporos Int. 2001 Dec;12(12):989-95
pubmed: 11846333
N Engl J Med. 2005 Jan 13;352(2):154-64
pubmed: 15647578
Urology. 2005 Sep;66(3):587-92
pubmed: 16140083
J Bone Miner Res. 2000 Apr;15(4):721-39
pubmed: 10780864
J Bone Miner Res. 2020 Oct;35(10):1871-1880
pubmed: 32542695
J Clin Oncol. 2007 Mar 20;25(9):1038-42
pubmed: 17369566
Asian J Androl. 2000 Mar;2(1):13-20
pubmed: 11228931
J Urol. 2002 Sep;168(3):1005-7
pubmed: 12187209
BJU Int. 2013 May;111(5):745-52
pubmed: 23331464
Arch Osteoporos. 2012;7:3-20
pubmed: 23203733
Lancet. 2015 Aug 1;386(9992):433-43
pubmed: 26040499
Cancer. 2005 Jan 15;103(2):237-41
pubmed: 15597384
J Bone Miner Res. 1996 Jul;11(7):984-96
pubmed: 8797120
Arch Osteoporos. 2015;10:231
pubmed: 26297076
Can J Urol. 2010 Jun;17(3):5170-7
pubmed: 20566009
JAMA. 2012 Jan 18;307(3):255-6
pubmed: 22253389
Kidney Int. 2008 Dec;74(11):1385-93
pubmed: 18685574
Int J Urol. 2019 Oct;26(10):980-984
pubmed: 31353680
Clin Genitourin Cancer. 2007 Mar;5(4):271-7
pubmed: 17553207
BMC Cancer. 2015 Nov 02;15:837
pubmed: 26525985
Aging Male. 2020 Nov 16;:1-6
pubmed: 33191830
Cancers (Basel). 2018 May 24;10(6):
pubmed: 29795015
J Bone Miner Metab. 2019 Jan;37(1):72-80
pubmed: 29313098
Arch Intern Med. 2005 Nov 14;165(20):2414-9
pubmed: 16287772
J Bone Miner Metab. 2020 Mar;38(2):141-144
pubmed: 32020289
N Engl J Med. 2009 Aug 20;361(8):745-55
pubmed: 19671656
J Bone Miner Res. 2010 Oct;25(10):2239-50
pubmed: 20499357